{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T05:23:22Z","timestamp":1787289802516,"version":"build-2736575974"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced hand-foot syndrome (HFS) is a common dose-limiting cutaneous adverse reaction associated with cytotoxic agents such as capecitabine and small-molecule targeted drugs. Severe HFS may lead to dose reduction or interruption of antitumor treatment, significantly impairing patients' quality of life and treatment compliance. Current standard treatments (urea ointment, vitamin B6, topical corticosteroids, etc.) show limited efficacy for some patients with moderate-to-severe HFS, creating an urgent clinical need for additional supportive interventions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a single-arm prospective interventional pilot study. It enrolled 30 consecutive patients with solid tumors who received capecitabine-based antitumor therapy or oral targeted therapy, developed HFS \u2265 grade 1, and were refractory to standard treatment between November 1, 2025 and April 2026 at the Department of Medical Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine. All patients received a prespecified combined regimen consisting of self-formulated Yiqi Huoxue Tongluo herbal bath and external arnebia oil. Source-record review showed that the external treatment was initiated during the antitumor drug administration period; for patients receiving capecitabine, treatment generally began on cycle day 2\u20133 rather than during a scheduled rest period. The primary endpoint was the observed response rate, defined as a reduction in HFS grade by \u22651 grade. Secondary endpoints included complete remission rate, time to improvement, proportion of patients maintaining the original capecitabine dose, two-cycle follow-up recurrence\/worsening, and safety. Missing efficacy data were described without imputation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty patients were enrolled, with a mean age of 59.0\u00b112.4 years and 60.0% male. Baseline HFS grade was grade 1 in 2 patients (6.7%), grade 2 in 24 (80.0%), and grade 3 in 4 (13.3%). Twenty-eight patients had complete efficacy evaluation. The observed overall response rate was 85.7% (24\/28), complete remission rate was 7.1% (2\/28), and the mean reduction in HFS grade was 0.9. The median time to improvement was 7 days (range 3\u201328 days). In total, 82.1% (23\/28) of evaluable patients maintained the original antitumor regimen without capecitabine dose reduction. During two subsequent treatment cycles of follow-up, no recurrence or worsening of HFS was documented; four patients discontinued capecitabine because of disease change, and 25 patients continued the original capecitabine dose. No severe adverse events related to the combined external regimen were observed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Yiqi Huoxue Tongluo herbal bath combined with external arnebia oil showed preliminary signals of effectiveness and favorable safety in chemotherapy-induced HFS refractory to standard treatment. Because this single-arm pilot study lacked a concurrent control group, causal inference is limited and the findings should be interpreted as hypothesis-generating pending confirmation in controlled prospective trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1900383","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:12Z","timestamp":1787286192000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of traditional Chinese medicine herbal hand-foot bath combined with arnebia oil for chemotherapy-induced hand-foot syndrome refractory to standard treatment: a single-arm prospective interventional pilot study of 30 cases"],"prefix":"10.3389","volume":"13","author":[{"given":"Ying","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqi","family":"Jin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Intervention, Department of Medical Oncology, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]},{"name":"Zhejiang Provincial Clinical Research Center for CANCER","place":["Hangzhou, China"]},{"name":"Cancer Center of Zhejiang University","place":["Hangzhou, China"]},{"name":"Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linglin","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Shao","sequence":"additional","affiliation":[{"name":"Department of Nursing, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Tan","sequence":"additional","affiliation":[{"name":"Key Laboratory of Cancer Prevention and Intervention, Department of Medical Oncology, Ministry of Education, The Second Affiliated Hospital, Zhejiang University School of Medicine","place":["Hangzhou, Zhejiang, China"]},{"name":"Zhejiang Provincial Clinical Research Center for CANCER","place":["Hangzhou, China"]},{"name":"Cancer Center of Zhejiang University","place":["Hangzhou, China"]},{"name":"Center for Medical Research and Innovation in Digestive System Tumors, Ministry of Education","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1080\/14740338.2016.1238067","article-title":"Incidence and implications of chemotherapy related hand-foot syndrome","volume":"15","author":"Nikolaou","year":"2016","journal-title":"Expert Opin Drug Saf."},{"key":"B2","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol."},{"key":"B3","unstructured":"NCCN Clinical Practice Guidelines in Oncology: Supportive Care, Version 2.\n          \n          2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e1575","DOI":"10.1136\/spcare-2022-004011","article-title":"Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis\u2013systematic review and Bayesian network meta-analysis","volume":"14","author":"Ramasubbu","year":"2024","journal-title":"BMJ Support Palliat Care."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1534735418817833","DOI":"10.1177\/1534735418817833","article-title":"Integrative herbal medicine for chemotherapy-induced peripheral neuropathy and hand-foot syndrome in colorectal cancer: a systematic review and meta-analysis","volume":"18","author":"Liu","year":"2019","journal-title":"Integr Cancer Ther."},{"key":"B6","doi-asserted-by":"publisher","first-page":"15347354231168796","DOI":"10.1177\/15347354231168796","article-title":"The efficacy and safety of the Shouzu Ning Decoction treatment versus halometasone plus celecoxib treatment in patients with grade 2 HFSR: a randomized clinical trial","volume":"22","author":"Shou","year":"2023","journal-title":"Integr Cancer Ther."},{"key":"B7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.13288\/j.11-2166\/r.2022.06.019","article-title":"Expert consensus on syndromes, treatment methods, formulas and medicinals of hand-foot syndrome in traditional Chinese medicine","volume":"63","author":"Jia","year":"2022","journal-title":"J Tradit Chin Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"154667","DOI":"10.1016\/j.phymed.2023.154667","article-title":"Astragalus polysaccharide ameliorates vascular endothelial dysfunction by stimulating macrophage M2 polarization via potentiating Nrf2\/HO-1 signaling pathway","volume":"112","author":"Sha","year":"2023","journal-title":"Phytomedicine."},{"key":"B9","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.\n          \n          2017"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e3633","DOI":"10.1002\/jgm.3633","article-title":"Shikonin potentiates skin wound healing in Sprague\u2013Dawley rats by stimulating fibroblast and endothelial cell proliferation and angiogenesis","volume":"26","author":"Xue","year":"2024","journal-title":"J Gene Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev."},{"key":"B12","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2147\/OTT.S510766","article-title":"Management of regorafenib-induced hand-foot skin reaction with topical Chinese medicine and urea ointment: a case report and literature review","volume":"18","author":"Liu","year":"2025","journal-title":"Onco Targets Ther."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T04:23:15Z","timestamp":1787286195000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1900383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":12,"alternative-id":["10.3389\/fmed.2026.1900383"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1900383","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1900383"}}